GENI
Genius Sports Limited
GENI offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
TMUS
T-Mobile US, Inc.
TMUS has the edge over GENI overall, supported by stronger valuation and lower modeled downside.
GENI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Strong |
GENI's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
TMUS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Strong |
TMUS's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
GENI PE Valuation
GENI has no meaningful PE right now: it lost money over the past year.
TMUS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $171 | — |
| Current | 16x | $171 | — |
| Cheap | 21x | $218 | +27% |
| Fair | 26x | $274 | +60% |
| Expensive | 56x | $581 | +240% |
Historical ranges are pointers, not guarantees.
TMUS's PE is in its cheap range at 16x. If earnings grow as analysts expect, today's price would be 13x next year's earnings.
GENI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect GENI's losses to grow, with revenue growing. However, they disagree widely on these estimates.
TMUS Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
TMUS has the edge over GENI on the outlook, with more favorable earnings and profitability expectations.
GENI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.68 | -$0.37 |
| Q1 2026 | -$0.61 | -$0.42 |
| Q4 2025 | -$0.43 | -$0.16 |
| Q3 2025 | -$0.47 | -$0.15 |
| Q2 2025 | -$0.31 | +$0.12 |
| Q1 2025 | -$0.19 | +$0.20 |
| Q4 2024 | -$0.27 | +$0.13 |
| Q3 2024 | -$0.32 | +$0.54 |
GENI is still losing money, but far less than before: $0.68 per share over the past year, against $3.94 at its worst in early 2022.
TMUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.49 | +30% |
| Q3 2026 | $10.37 | -0.2% |
| Q2 2026 | $9.56 | -9.7% |
| Q1 2026 | $9.41 | -8.1% |
| Q4 2025 | $9.72 | +0.6% |
| Q3 2025 | $10.39 | +18% |
| Q2 2025 | $10.59 | +33% |
| Q1 2025 | $10.24 | +39% |
| Q4 2024 | $9.66 | +39% |
TMUS has the edge over GENI on earnings quality, reporting a profit while its opponent remains loss making.
GENI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $195.5M | +65% |
| Q1 2026 | $188M | +31% |
| Q4 2025 | $240.5M | +37% |
| Q3 2025 | $166.3M | +38% |
| Q2 2025 | $118.7M | +24% |
| Q1 2025 | $144M | +20% |
| Q4 2024 | $175.5M | +38% |
| Q3 2024 | $120.2M | +18% |
GENI has the edge over TMUS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -14% | +54 points |
| Q1 2026 | -16% | -1.6 points |
| Q4 2025 | -8.4% | -4.3 points |
| Q3 2025 | -14% | -8.8 points |
| Q2 2025 | -68% | -46 points |
| Q1 2025 | -14% | +6.1 points |
| Q4 2024 | -4.1% | +23 points |
| Q3 2024 | -5% | +3.7 points |
GENI's operating margin was −14% last quarter, up 54 points from the same quarter a year ago.
TMUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $23.6B | +7.4% |
| Q2 2026 | $22.8B | +7.9% |
| Q1 2026 | $23.1B | +11% |
| Q4 2025 | $24.3B | +11% |
| Q3 2025 | $22B | +8.9% |
| Q2 2025 | $21.1B | +6.9% |
| Q1 2025 | $20.9B | +6.6% |
| Q4 2024 | $21.9B | +6.8% |
TMUS's revenue has grown year over year for 10 quarters in a row: $23.6B last quarter, up 7.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +3.4 points |
| Q2 2026 | 24% | -0.6 points |
| Q1 2026 | 19% | -3.5 points |
| Q4 2025 | 15% | -5.6 points |
| Q3 2025 | 21% | -3.2 points |
| Q2 2025 | 25% | +1.3 points |
| Q1 2025 | 23% | +2.6 points |
| Q4 2024 | 21% | +4 points |
TMUS has the edge over GENI on profitability, with a higher operating margin.
GENI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$87M | -$67.8M |
| Q1 2026 | -$68.2M | -$20M |
| Q4 2025 | $69.6M | -0.4% |
| Q3 2025 | $19.1M | +$41.8M |
| Q2 2025 | -$19.2M | -$16.5M |
| Q1 2025 | -$48.3M | -$21.3M |
| Q4 2024 | $69.9M | +559% |
| Q3 2024 | -$22.7M | -7493% |
GENI has burned cash in most quarters: −$66M over the past year, against −$20M the year before.
TMUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +5.3% |
| Q2 2026 | $4.8B | +4.4% |
| Q1 2026 | $4.6B | +4.6% |
| Q4 2025 | $4.2B | +25% |
| Q3 2025 | $4.8B | +15% |
| Q2 2025 | $4.6B | +32% |
| Q1 2025 | $4.4B | +79% |
| Q4 2024 | $3.3B | +2% |
TMUS has the edge over GENI on cash generation, producing positive trailing cash flow while its opponent burns cash.
GENI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.5% | +9.5M shares |
| 1 year | +10% | +25.7M shares |
| 3 years | +34% | +70.4M shares |
| 5 years | +85% | +128M shares |
| Available history | +56% | +100M shares |
GENI has 279M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
GENI hasn't bought back shares in the past year.
TMUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -10.8M shares |
| 1 year | -4.9% | -55M shares |
| 3 years | -8.8% | -103M shares |
| 5 years | -15% | -182M shares |
| Available history | +24% | +207M shares |
TMUS has the edge over GENI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2.4B |
| Q2 2026 | $2.3B |
| Q1 2026 | $4.8B |
| Q4 2025 | $2.4B |
| Q3 2025 | $2.5B |
| Q2 2025 | $2.6B |
| Q1 2025 | $2.5B |
| Q4 2024 | $4.7B |
TMUS spent $12B buying back its own shares over the past year, down 1.7% from the year before.
GENI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -12.5x | Net Cash |
| Q4 2024 | -6.3x | Net Cash |
| Q1 2024 | -7.5x | Net Cash |
| Q4 2023 | -15.2x | Net Cash |
| Q1 2021 | 4.3x | High |
| Q4 2020 | 5.5x | High |
| Q3 2020 | 9.1x | High |
GENI has more cash than debt.
TMUS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.0x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 2.5x | Moderate |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | 2.4x | Moderate |
TMUS's net debt is less than a year of its operating earnings (EBITDA).
GENI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.6 | Neutral |
| Stochastic | 23.4 | Neutral |
GENI's weekly RSI is 46 (neutral) and its Stochastic is 23 (neutral).
TMUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.9 | Neutral |
| Stochastic | 42.1 | Neutral |
TMUS's weekly RSI is 48 (neutral) and its Stochastic is 42 (neutral).
GENI PE vs Communication Services Sector
GENI has no meaningful PE right now: it lost money over the past year.
TMUS PE vs Communication Services Sector
| Metric | TMUS | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 16x | Same PE |
| PE % | 1 | 26 | 25 pts below |
TMUS is trading at 16x earnings, in line with the Communication Services sector's median of 16x.
GENI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.28 | 2.9% below |
| 20 week MA | $6.73 | 9.4% below |
| 50 week MA | $6.77 | 9.9% below |
| 100 week MA | $8.60 | 29% below |
| 200 week MA | $7.35 | 17% below |
GENI is in a downtrend: it's below all five of its weekly moving averages, and 17% below its 200-week average.
TMUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $159.1 | 7.5% above |
| 20 week MA | $172.0 | 0.5% below |
| 50 week MA | $187.8 | 8.9% below |
| 100 week MA | $212.9 | 20% below |
| 200 week MA | $188.7 | 9.4% below |
TMUS has the edge over GENI on trend strength, trading above more of its moving averages.
GENI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $16.6 | +68% |
| 2021 | $16.6 | $7.61 | -54% |
| 2022 | $7.61 | $3.27 | -57% |
| 2023 | $3.27 | $6.18 | +89% |
| 2024 | $6.18 | $8.75 | +42% |
| 2025 | $8.75 | $10.9 | +24% |
| 2026 YTD | $10.9 | $6.10 | -44% |
GENI is down 44% so far in 2026, after finishing higher in four of the previous six years.
TMUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $77.2 | $132.9 | +72% |
| 2021 | $132.9 | $119.9 | -9.8% |
| 2022 | $119.9 | $140.0 | +17% |
| 2023 | $140.0 | $160.3 | +15% |
| 2024 | $160.3 | $223.0 | +39% |
| 2025 | $223.0 | $201.0 | -9.9% |
| 2026 YTD | $201.0 | $171.0 | -15% |
TMUS has the edge over GENI on returns for 2026, with the stronger performance.